

Global Oral Biologics and Biosimilars Market Poised for Significant Growth, Reaching \$13.68 Billion by 2027

The Business Research Company's Oral Biologics And Biosimilars Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

LANDON, GREATER LONDON, UK, December 11, 2023 /EINPresswire.com/ -- The [global oral biologics and biosimilars market](#) is strategically segmented based on therapy, disease, molecule type, and distribution channel. With a compound annual growth rate (CAGR) of 20.3%, the market size is expected to surge from \$5.37 billion in 2022 to \$6.47 billion in 2023. The growth momentum is projected to continue, reaching a market size of \$13.68 billion by 2027 with a CAGR of 20.6%.

“

The global oral biologics and biosimilars market size will grow from \$5.37 billion in 2022 to \$6.47 billion in 2023 at a compound annual growth rate (CAGR) of 20.3%.”

The Business Research Company

Key Segments Shaping the Oral Biologics and Biosimilars Landscape

1. Therapy Segmentation: The market is categorized by therapy into Lymphocyte Modulators, Interleukin

Inhibitors, and Tumor Necrosis Factor-Alpha Inhibitors. These therapies cater to various diseases by targeting specific biological pathways.

2. Disease Breakdown: Diseases addressed by oral biologics and biosimilars include Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis, and Other Diseases. These treatments offer innovative solutions for a broad spectrum of medical conditions.

3. Molecule Type Differentiation: Molecule types in the market encompass Vaccines, Proteins and Peptides, Monoclonal Antibodies, and Other Molecule Types. These diverse molecule types contribute to the varied therapeutic approaches in oral biologics and biosimilars.

4. Distribution Channel Classification: The market addresses distribution through Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. This multi-channel distribution ensures accessibility and availability to a wide range of consumers.

Driving Forces: Rising Prevalence of Chronic Diseases

The growth of the oral biologics and biosimilars market is propelled by the increasing prevalence of chronic diseases such as arthritis, asthma, and cancer. Unhealthy lifestyles, sedentary habits, and long working hours contribute to the surge in chronic diseases. Biologics and biosimilars play a crucial role in the treatment of these conditions, stimulating the immune system to combat cancer cells. The United Nations predicts that by 2030, chronic diseases will account for 70% of all fatalities globally. This rising prevalence of chronic diseases is a significant driver for the growth of the biologics and biosimilars market.

Explore the global landscape of Oral Biologics and Biosimilars with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=6830&type=smp

Major Market Players: Leaders in Biologics and Biosimilars Innovation

Key players in the oral biologics and biosimilars market include Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, and Emisphere Technologies. These industry leaders are at the forefront of innovation, driving advancements in biologics and biosimilars.

Trends: Creation of New Insulin Biosimilars

A key trend in the market is the creation of new insulin biosimilars. Major players are investing in developing biosimilars of insulin to capture market share. Biocon, an Indian biopharmaceutical company, launched interchangeable biosimilars insulin in November 2021, catering to patients with type 1 and type 2 diabetes.

Regional Dynamics: North America Leads, Middle East Emerges as Fastest-Growing Region

In 2022, North America held the largest share in the oral biologics and biosimilars market. However, the Middle East is anticipated to be the fastest-growing region during the forecast period, reflecting significant shifts in the global market landscape. The comprehensive report provides detailed insights into regional dynamics, market trends, and growth opportunities across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Access the complete report for an in-depth analysis of the global Oral Biologics and Biosimilars market: <https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars->

Global Oral Biologics And Biosimilars Market



Expected Growth Rate Through 2027
20.6%

Expected Market Size By 2027
\$13.68 Bn





The rising prevalence of chronic diseases
Is the main driver of the market

North America
is the largest region in the market



Information sourced from The Business Research Company
thebusinessresearchcompany.com

Disclaimer: The data in this infographic are believed to be accurate as of the date of publication and cannot be guaranteed. The Business Research Company is not responsible for any errors or omissions in this infographic. The infographic is for informational purposes only and should not be used as a basis for investment decisions. The infographic is not intended to be used as a basis for investment decisions. The infographic is not intended to be used as a basis for investment decisions. The infographic is not intended to be used as a basis for investment decisions.

Oral Biologics And Biosimilars Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

[Oral Biologics & Biosimilars Global Market Report 2023](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Oral Biologics & Biosimilars Global Market Report 2023 by The Business Research Company is the most comprehensive report that provides insights on oral biologics and biosimilars market size, oral biologics and biosimilars market drivers and oral biologics and biosimilars market trends, oral biologics and biosimilars market major players, oral biologics and biosimilars market share, oral biologics and biosimilars market strategies, oral biologics and biosimilars market competitors' revenues, oral biologics and biosimilars market positioning, and oral biologics and biosimilars market growth across geographies. The oral biologics and biosimilars market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By [The Business Research Company](#):

Hematology Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report>

Dermatology Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report>

Generic Pharmaceuticals Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report>

About The Business Research Company

The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market

intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <https://blog.tbrc.info/>

Healthcare Blog: <https://healthcareresearchreports.com/>

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/673482307>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.